arrow
G

Gautam Borthakur

university of texas system
H指数:92
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS

口服三联方案(地西他滨/西达苯胺、维奈克拉和吉列替尼)用于新诊断和复发/难治性FLT3突变急性髓系白血病及高风险骨髓增生异常综合征

2026-10-130
OAAI
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Blinatumomab和Ponatinib与Hyper-CVAD和Ponatinib在初诊费城染色体阳性急性淋巴细胞白血病的成人患者中的比较:一项倾向性评分分析

2026-04-010
PRE
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

克拉屈滨联合低剂量阿糖胞苷和维奈克拉,与阿扎胞苷和维奈克拉交替用于新诊断急性髓系白血病

2026-04-010
PRE
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML

评估减少一线强化疗联合Venetoclax巩固治疗周期对AML预后的影响

2026-03-040
OAAI
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

DS-1594 menin抑制剂的1/2期研究:在复发/难治性急性白血病中的应用

2025-11-270
OAAI
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

2025年白血病研究进展回顾:通过MD Anderson白血病研究视角进行审视

Cancer
IF5.1
2025-10-230
OAAI
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study

异基因造血细胞移植在新时代晚期系统性肥大细胞增生症中的应用:一项CIBMTR研究

2025-09-220
PRE
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

MECOM融合伙伴和骨髓原始细胞百分比影响MECOM重排急性髓系白血病患者预后

2025-09-220
PRE
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML

FLT3突变急性髓系白血病一线FLT3抑制剂为基础治疗后复发及复发后结局的细胞分子机制

2025-09-020
PREAI
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

NPM1突变急性髓系白血病经维奈克拉为基础的治疗后的结局与复发模式

2025-08-280
PREAI
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax

新诊断IDH突变型AML成人患者接受强化化疗和维奈克拉治疗后的结局

Leukemia
IF13.4
2025-08-140
PRE
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation

新诊断的FLT3酪氨酸激酶域突变急性髓系白血病患者的结局:NPM1共突变的治疗意义

Cancer
IF5.1
2025-08-090
OAAI
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia

新诊断急性髓系白血病八旬以上患者当代预后

Cancer
IF5.1
2025-08-070
OAAI
CD123 expression and its correlation with mutation profile in acute myeloid leukaemia

CD123表达及其与急性髓系白血病突变谱的相关性

2025-07-300
PRE
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy

红系为主的骨髓增生异常肿瘤表现出独特的基因组景观,在维奈克拉为基础的治疗后预后较差。

Leukemia
IF13.4
2025-07-210
PRE
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia

RAS通路突变在慢性髓单核细胞白血病中的景观及临床病理特征

2025-07-150
OAAI
BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

BLAST:一种适用于全球范围且分子上具有多样性的慢性髓系单核细胞白血病患者生存模型

Blood
IF23.1
2025-05-090
PRE